Quality Control of Fetal Wharton’s Jelly Mesenchymal Stem Cells-Derived Small Extracellular Vesicles
Open Access
- 1 February 2025
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 1807-1820
Abstract
Background: Quality control (QC) is an important element in ensuring drug substances’ safety, efficacy, and quality. The dosing regimen for sEVs can be in the form of protein concentration or the number of particles based on the results of a series of quality controls applied as in-process control. Methods: Wharton’s Jelly Mesenchymal Stem Cells (WJMSCs) were isolated from four independent umbilical cord samples and were characterized following the International Society for Cellular Therapy (ISCT) guidelines. Small extracellular vesicles (sEVs) were isolated separately from these four WJMSCs samples using the Tangential Flow Filtration (TFF) method and were characterized per Minimal Information for Studies of Extracellular Vesicles (MISEV2018) guidelines. Each isolated and concentrated sEV preparation was standardized and its purity was determined by the ratio of the number of particles to protein concentration. Results: All the WJMSCs samples passed the Mesenchymal Stem Cells (MSCs) characterization QC tests. Qualitatively, EVs-positive markers (CD63 and TSG101) and intact bilipid membrane vesicles were detected in all the sEV preparations. Quantitatively, the protein and particle concentrations revealed that all the sEV preparations were “impure” with < 1.5 × 109 particles/μg protein. Albumin was co-isolated in all the sEV preparations. Conclusion: In short, all characterized and standardized individual and pooled sEV preparations were deemed “impure” due to albumin co-isolation using the TFF method. For therapeutic development, it is essential to report protein and particle concentrations in EV preparations based on these QC results.Keywords
This publication has 41 references indexed in Scilit:
- Quality and Safety Considerations for Therapeutic Products Based on Extracellular VesiclesPharmaceutical Research, 2024
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approachesJournal of Extracellular Vesicles, 2024
- Small extracellular vesicles derived from human adipose‐derived mesenchymal stromal cells cultured in a new chemically‐defined contaminate‐free media exhibit enhanced biological and therapeutic effects on human chondrocytes in vitro and in a mouse osteoarthritis modelJournal of Extracellular Vesicles, 2023
- Large‐scale production of extracellular vesicles: Report on the “massivEVs” ISEV workshopJournal of Extracellular Biology, 2022
- Reproducibility of extracellular vesicle researchEuropean Journal of Cell Biology, 2022
- A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulationJournal of Extracellular Vesicles, 2022
- The functional role of soluble proteins acquired by extracellular vesiclesJournal of Extracellular Biology, 2022
- Dosing extracellular vesiclesAdvanced Drug Delivery Reviews, 2021
- Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular originJournal of Extracellular Vesicles, 2021
- Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular VesiclesStem Cells Translational Medicine, 2017